Company Filing History:
Years Active: 2011-2012
Title: Guo-Qiang Lin: Innovating Metallo-Proteins in Shanghai
Introduction
Guo-Qiang Lin is a distinguished inventor based in Shanghai, China, who has made significant contributions to the field of pharmaceutical innovation. With a focus on developing inhibitors for metalloproteinases, his work holds promise for treating obstructive airway diseases, including chronic obstructive pulmonary disease (COPD).
Latest Patents
Lin holds two notable patents related to his research. The first patent, titled "(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors," focuses on compounds that inhibit metalloproteinase MMP-12. These compounds are beneficial in the treatment of obstructive airway diseases. The second patent, "(2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors," presents a similar focus on inhibitors of metalloproteinase MMP-12, also aimed at addressing respiratory conditions like COPD.
Career Highlights
Guo-Qiang Lin works at Medivir AB, a company that specializes in the development of innovative medicines for the treatment of serious infectious diseases. His work has led to advancements in the pharmaceutical industry, particularly regarding the treatment of complex airway diseases through innovative chemical compounds.
Collaborations
In his endeavors, Lin has collaborated with notable colleagues, including Hans Kristian Wallberg and Ming-Hua Xu. Their collective expertise and efforts contribute to the successful development of groundbreaking treatments aimed at improving patient outcomes.
Conclusion
Guo-Qiang Lin exemplifies the spirit of innovation in Shanghai through his vital contributions to the pharmaceutical industry. His patents reflect a commitment to addressing critical health challenges, showcasing the impact that dedicated inventors can have on improving health and wellness globally.